TY - JOUR
T1 - Retrospective application of the Milan System for reporting salivary gland cytopathology
T2 - A Cancer Center experience
AU - Leite, Amanda Almeida
AU - Vargas, Pablo Agustin
AU - dos Santos Silva, Alan Roger
AU - Galvis, Marisol Miranda
AU - de Sá, Raisa Sales
AU - Lopes Pinto, Clóvis Antonio
AU - Kowalski, Luiz Paulo
AU - Saieg, Mauro
N1 - Funding Information:
This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES/PROEX, Brazil).
Funding Information:
This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES/PROEX, Brazil).
Publisher Copyright:
© 2020 Wiley Periodicals, Inc.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was recently proposed. Herein, we retrospectively applied this nomenclature system to salivary gland lesions sampled by ultrasound-guided fine-needle aspiration (FNA). Methods: All cases of salivary gland FNA with available surgical follow-up, in the period from 2014 to 2017 at our institution were reviewed and reclassified according to one of the six categories of the MSRSGC, blind to the surgical outcome. Overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated, as well as risks of neoplasm (RON) and risk of malignancy (ROM) for each of the proposed categories. Results: There were 104 salivary gland lesions, with a female predominance (57.7%), most cases from the parotid gland (89.4%). Mean age was 53.2 years. Distribution of the specimens according to the Milan System was as follows: 19.2% nondiagnostic (ND), 8.7% non-neoplastic (NN), 9.6% atypia of undetermined significance (AUS), 40.4% benign neoplasm (BN), 14.4% salivary gland neoplasm of uncertain malignant potential (SUMP), 1.9% suspicious for malignancy (SFM), and 5.8% malignant. Sensitivity, specificity, PPV, and NPV using MSRSGC were calculated as 75%, 98.4%, 88.9%, and 95.3%, respectively. RON/ROM for each category were 60%/15% for ND, 44.4%/0% for NN, 90%/40% for AUS, 100%/9.5% for BN, 100%/13.3% for SUMP, 50%/50% for SFM and 100%/100% for malignant. Conclusion: The use of the Milan System proved to be a useful method to predict the risk of neoplasm and malignancy in the sample studied, with high sensitivity and specificity.
AB - Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was recently proposed. Herein, we retrospectively applied this nomenclature system to salivary gland lesions sampled by ultrasound-guided fine-needle aspiration (FNA). Methods: All cases of salivary gland FNA with available surgical follow-up, in the period from 2014 to 2017 at our institution were reviewed and reclassified according to one of the six categories of the MSRSGC, blind to the surgical outcome. Overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated, as well as risks of neoplasm (RON) and risk of malignancy (ROM) for each of the proposed categories. Results: There were 104 salivary gland lesions, with a female predominance (57.7%), most cases from the parotid gland (89.4%). Mean age was 53.2 years. Distribution of the specimens according to the Milan System was as follows: 19.2% nondiagnostic (ND), 8.7% non-neoplastic (NN), 9.6% atypia of undetermined significance (AUS), 40.4% benign neoplasm (BN), 14.4% salivary gland neoplasm of uncertain malignant potential (SUMP), 1.9% suspicious for malignancy (SFM), and 5.8% malignant. Sensitivity, specificity, PPV, and NPV using MSRSGC were calculated as 75%, 98.4%, 88.9%, and 95.3%, respectively. RON/ROM for each category were 60%/15% for ND, 44.4%/0% for NN, 90%/40% for AUS, 100%/9.5% for BN, 100%/13.3% for SUMP, 50%/50% for SFM and 100%/100% for malignant. Conclusion: The use of the Milan System proved to be a useful method to predict the risk of neoplasm and malignancy in the sample studied, with high sensitivity and specificity.
KW - fine-needle aspiration
KW - Milan System
KW - salivary gland
UR - http://www.scopus.com/inward/record.url?scp=85085118025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085118025&partnerID=8YFLogxK
U2 - 10.1002/dc.24464
DO - 10.1002/dc.24464
M3 - Article
C2 - 32374949
AN - SCOPUS:85085118025
SN - 8755-1039
VL - 48
SP - 821
EP - 826
JO - Diagnostic Cytopathology
JF - Diagnostic Cytopathology
IS - 9
ER -